{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:19:49Z","timestamp":1789755589812,"version":"4.0.1"},"reference-count":44,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["306193\/2018-3"],"award-info":[{"award-number":["306193\/2018-3"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["E-26\/202.805\/2017 and E-26\/200.861\/2021"],"award-info":[{"award-number":["E-26\/202.805\/2017 and E-26\/200.861\/2021"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfeicoamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Imatinib (IMT) is the first-in-class BCR-ABL commercial tyrosine kinase inhibitor (TKI). However, the resistance and toxicity associated with the use of IMT highlight the importance of the search for new TKIs. In this context, heterocyclic systems, such as quinoline, which is present as a pharmacophore in the structure of the TKI inhibitor bosutinib (BST), have been widely applied. Thus, this work aimed to obtain new hybrids of imatinib containing quinoline moieties and evaluate them against K562 cells. The compounds were synthesized with a high purity degree. Among the produced molecules, the inhibitor 4-methyl-N3-(4-(pyridin-3-yl)pyrimidin-2-yl)-N1-(quinolin-4-yl)benzene-1,3-diamine (2g) showed a suitable reduction in cell viability, with a CC50 value of 0.9 \u00b5M (IMT, CC50 = 0.08 \u00b5M). Molecular docking results suggest that the interaction between the most active inhibitor 2g and the BCR-ABL1 enzyme occurs at the bosutinib binding site through a competitive inhibition mechanism. Despite being less potent and selective than IMT, 2g is a suitable prototype for use in the search for new drugs against chronic myeloid leukemia (CML), especially in patients with acquired resistance to IMT.<\/jats:p>","DOI":"10.3390\/ph15030309","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T20:36:30Z","timestamp":1646339790000},"page":"309","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Hybrids of Imatinib with Quinoline: Synthesis, Antimyeloproliferative Activity Evaluation, and Molecular Docking"],"prefix":"10.3390","volume":"15","author":[{"given":"Carine","family":"Santos","sequence":"first","affiliation":[{"name":"Laborat\u00f3rio de Sintese de Farmacos-LASFAR, Instituto de Tecnologia em Farmacos-Farmanguinhos, FIOCRUZ, Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro 21041-250, Brazil"},{"name":"Programa de P\u00f3s-gradua\u00e7\u00e3o em Farmacologia e Qu\u00edmica Medicinal do Instituto de Ci\u00eancias Biom\u00e9dicas\u2013ICB-UFRJ, Centro de Ci\u00eancias da Sa\u00fade-CCS, Bloco J, Ilha do Fund\u00e3o, Rio de Janeiro 21941-902, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7850-3888","authenticated-orcid":false,"given":"Luiz","family":"Pimentel","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Sintese de Farmacos-LASFAR, Instituto de Tecnologia em Farmacos-Farmanguinhos, FIOCRUZ, Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro 21041-250, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henayle","family":"Canzian","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Sintese de Farmacos-LASFAR, Instituto de Tecnologia em Farmacos-Farmanguinhos, FIOCRUZ, Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro 21041-250, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andressa","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Sintese de Farmacos-LASFAR, Instituto de Tecnologia em Farmacos-Farmanguinhos, FIOCRUZ, Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro 21041-250, Brazil"},{"name":"Programa de P\u00f3s-gradua\u00e7\u00e3o em Farmacologia e Qu\u00edmica Medicinal do Instituto de Ci\u00eancias Biom\u00e9dicas\u2013ICB-UFRJ, Centro de Ci\u00eancias da Sa\u00fade-CCS, Bloco J, Ilha do Fund\u00e3o, Rio de Janeiro 21941-902, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4560-1291","authenticated-orcid":false,"given":"Floriano","family":"Junior","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Bioqu\u00edmica Experimental e Computacional de F\u00e1rmacos, Instituto Oswaldo Cruz FIOCRUZ, Av. Brasil 4365, Manguinhos, Rio de Janeiro 21040-360, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Dantas","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Bioqu\u00edmica Experimental e Computacional de F\u00e1rmacos, Instituto Oswaldo Cruz FIOCRUZ, Av. Brasil 4365, Manguinhos, Rio de Janeiro 21040-360, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Hoelz","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Sintese de Farmacos-LASFAR, Instituto de Tecnologia em Farmacos-Farmanguinhos, FIOCRUZ, Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro 21041-250, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Marinho","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Sintese de Farmacos-LASFAR, Instituto de Tecnologia em Farmacos-Farmanguinhos, FIOCRUZ, Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro 21041-250, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1336-5928","authenticated-orcid":false,"given":"Anna","family":"Cunha","sequence":"additional","affiliation":[{"name":"Departamento de Qu\u00edmica Org\u00e2nica, Campus do Valonguinho, Universidade Federal Fluminense\u2013UFF, Niter\u00f3i 24020-150, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bastos","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Sintese de Farmacos-LASFAR, Instituto de Tecnologia em Farmacos-Farmanguinhos, FIOCRUZ, Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro 21041-250, Brazil"},{"name":"Programa de P\u00f3s-gradua\u00e7\u00e3o em Farmacologia e Qu\u00edmica Medicinal do Instituto de Ci\u00eancias Biom\u00e9dicas\u2013ICB-UFRJ, Centro de Ci\u00eancias da Sa\u00fade-CCS, Bloco J, Ilha do Fund\u00e3o, Rio de Janeiro 21941-902, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0146-2218","authenticated-orcid":false,"given":"Nubia","family":"Boechat","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Sintese de Farmacos-LASFAR, Instituto de Tecnologia em Farmacos-Farmanguinhos, FIOCRUZ, Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro 21041-250, Brazil"},{"name":"Programa de P\u00f3s-gradua\u00e7\u00e3o em Farmacologia e Qu\u00edmica Medicinal do Instituto de Ci\u00eancias Biom\u00e9dicas\u2013ICB-UFRJ, Centro de Ci\u00eancias da Sa\u00fade-CCS, Bloco J, Ilha do Fund\u00e3o, Rio de Janeiro 21941-902, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"key":"ref_1","first-page":"612","article-title":"Targeted Therapies: A Life Saving Approach for Cancer","volume":"5","author":"Mercy","year":"2016","journal-title":"World J. Pharm. Pharm. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1182\/blood-2008-04-149286","article-title":"Patients\u2019 age and BCR-ABL frequency in adult B-precursor ALL: A retrospective analysis from the GMALL study group","volume":"112","author":"Burnmeister","year":"2008","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1074\/jbc.R112.438382","article-title":"Structure and Dynamic Regulation of Abl Kinases","volume":"288","author":"Panjarian","year":"2013","journal-title":"Biol. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1126\/science.3263702","article-title":"Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors","volume":"242","author":"Yaish","year":"1988","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zhang, Q., Zhang, X., and You, Q. (2016). Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments. Molecules, 21.","DOI":"10.3390\/molecules21070879"},{"key":"ref_7","first-page":"267","article-title":"Leucemia mieloide cr\u00f3nica en crisis bl\u00e1stica: Perspectiva terap\u00e9utica seg\u00fan la evidencia (parte II)","volume":"10","author":"Rodriguez","year":"2006","journal-title":"Rev. Colomb. Cancerol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1080\/14737140.2018.1527688","article-title":"A comprehensive review of protein kinase inhibitors for cancer therapy","volume":"18","author":"Kannaiayan","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"djw003","DOI":"10.1093\/jnci\/djw003","article-title":"Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase after Generic Entry of Imatinib in the United States","volume":"108","author":"Padula","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: From chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ctrv.2011.07.004","article-title":"Phisician\u2019s guide to the clinical management of adverce events on nilotinib therapy for the treatment of CML","volume":"38","author":"Rosti","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1007\/s00044-017-1993-8","article-title":"Imatinib derivatives as inhibitors of K562 cells in chronic myeloid leukemia","volume":"26","author":"Azevedo","year":"2017","journal-title":"Med. Chem. Res."},{"key":"ref_14","first-page":"1","article-title":"A mini review of pyrimidine and fused pyrimidine marketed drugs","volume":"2","author":"Selvam","year":"2012","journal-title":"Res. Pharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0014-827X(01)01123-5","article-title":"Synthesis and antitumor evaluation of 6-thioxo-, -6-oxo- and 2,4-dioxopyrimidine derivatives","volume":"56","author":"Cocco","year":"2001","journal-title":"Farmaco"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejmech.2012.12.003","article-title":"Synthesis and biological evaluation of thieno[2\u2019,3\u2019:4,5]pyrimido[1,2-b][1,2,4]triazines and thieno[2,3-d][1,2,4]triazolo[1,5-a]pyrimidines as anti-inflamatory and analgesic agents","volume":"62","author":"Ashour","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13065-018-0406-5","article-title":"Therapeutic potential of heterocyclic pyrimidine scaffolds","volume":"12","author":"Kumar","year":"2018","journal-title":"Chem. Cent. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/1568026620666200124094949","article-title":"Phenylamino-pyrimidine (PAP) Privileged Structure: Synthesis and Medicinal Applications","volume":"20","author":"Pimentel","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"115973","DOI":"10.1016\/j.bmc.2020.115973","article-title":"A comprehensive review on the biological interest of quinoline and its derivatives","volume":"32","author":"Matada","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"104639","DOI":"10.1016\/j.bioorg.2021.104639","article-title":"Quinolines, a perpetual, multipurpose scaffold in medicinal chemistry","volume":"109","author":"Yadav","year":"2021","journal-title":"Bioorg. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Levinson, N.M., and Boxer, S.G. (2012). Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0029828"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e4628","DOI":"10.1002\/aoc.4628","article-title":"Quinoline and ferrocene conjugates: Synthesis, computational study and biological evaluations","volume":"33","author":"Bernardi","year":"2019","journal-title":"Appl. Organomet. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.bioorg.2018.10.064","article-title":"New quinolone\/chalcone hybrids as anti-cancer agents: Design, synthesis and evaluations of cytotoxicity and PI3K inhibitory activity","volume":"82","author":"Abbas","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejmech.2019.02.022","article-title":"Discovery of novel triazolo[4,3-b]pyridazin-3-il-quinoline derivatives as PIM inhibitors","volume":"168","author":"Oliva","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejmech.2017.03.064","article-title":"Design, synthesis and biological evaluation of quinolone derivatives as HDAC class I inhibitors","volume":"133","author":"Chen","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep44073","article-title":"Novel members of quinolone compound family enhance insulin secretion in RIN-5AH beta cells and in rat pancreatic islet microtissue","volume":"7","author":"Orfi","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1515\/acph-2015-0030","article-title":"Anti-breast cancer activityof some novel quinolone derivatives","volume":"65","author":"Ghorab","year":"2015","journal-title":"Acta Pharm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e22260","DOI":"10.1002\/jbt.22260","article-title":"Biological evaluation of some quinolone derivatives with different funcitional groups as anticancer agents","volume":"33","author":"Tekin","year":"2019","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref_29","unstructured":"Tang, Y., Wang, L., Xiang, J., and Liu, Y. (2014). An Application of 4-Substituted-quinoline-2-amine Compound in Preparation of Anticancer Drugs. (CN 104027335)."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Korcz, M., Saczewski, F., Bednarski, P.J., and Kornicka, A. (2018). Synthesis, Structure, Chemical Stability, and In Vitro Cytotoxic Properties of Novel Quinoline\u20143-Carbaldehyde Hydrazones Bearing a 1,2,4-triazole or Benzotriazole Moiety. Molecules, 23.","DOI":"10.3390\/molecules23061497"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.2174\/15680266113136660204","article-title":"Fluorinated Compounds Against Mycobacterium tuberculosis","volume":"13","author":"Boechat","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.bmcl.2016.01.068","article-title":"Synthesis and biological evaluation of 1,2,3-triazole and 1,3,4-oxadiazole derivatives of imatinib","volume":"26","author":"Li","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1158\/1535-7163.MCT-12-0302","article-title":"The Novel BCR-ABL and FLT3 Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2","volume":"11","author":"Sen","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"42","DOI":"10.15227\/orgsyn.029.0042","article-title":"Ethyl \u03b2-anilinocrotonate","volume":"29","author":"Reynolds","year":"1949","journal-title":"Org. Synth."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"380","DOI":"10.15227\/orgsyn.089.0380","article-title":"Preparation of H, 4PyrrolidineQuin-BAM (PBAM)","volume":"89","author":"Davis","year":"2012","journal-title":"Org. Synth."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1002\/cmdc.201100304","article-title":"N\u2014[2-Methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine as a scaffold for the synthesis of inhibitors of Bcr-Abl","volume":"6","author":"Arioli","year":"2011","journal-title":"ChemMedChem"},{"key":"ref_37","first-page":"2089","article-title":"Microwave Enhancement of a \u201cOne-pot\u201d Tandem Azidation-\u201cClick\u201d Cycloaddition of Anilines","volume":"14","author":"Moorhouse","year":"2008","journal-title":"Synlett"},{"key":"ref_38","unstructured":"Chen, Y., Rao, Z., Yang, C., Bai, C., Pan, C., Meng, F., Zhang, W., Wang, T., Wang, S., and Liu, H. (2013). 1,4-Dissubstituted-1,2,3-triazole Compounds and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of Leukemia. (CN 103159739)."},{"key":"ref_39","unstructured":"Yeon, K.D., Jim, C.D., Yeol, L.G., Yeop, K.H., Hun, W.S., Fon, L.H., Mu, K.S., and Am, C. (2012). Isothiocyanate Compound Containin N-Phenylpyrimidin-2-amine Moiety and Method for the Preparation Thereof. (KR20120052095A)."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.3762\/bjoc.17.144","article-title":"(Phenylamino)pyrimidine-1,2,3-triazole derivatives as analogs of imatinib: Searching for novel compounds against chronic myeloid leukemia","volume":"17","author":"Pimentel","year":"2021","journal-title":"Beilstein J. Org. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1046\/j.1432-1327.2000.01606.x","article-title":"Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity","volume":"267","author":"Wilson","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.str.2019.05.012","article-title":"Continuous Evaluation of Ligand Protein Predictions: A Weekly Community Challenge for Drug Docking","volume":"27","author":"Wagner","year":"2019","journal-title":"Structure"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chembiol.2010.12.013","article-title":"Discovery and Characterization of a Cell-Permeable, Small-Molecule c-Abl Kinase Activator that Binds to the Myristoyl Binding Site","volume":"18","author":"Yang","year":"2011","journal-title":"Chem. Biol."},{"key":"ref_44","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinocarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/3\/309\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:31:42Z","timestamp":1760135502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/3\/309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["ph15030309"],"URL":"https:\/\/doi.org\/10.3390\/ph15030309","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,3]]}}}